297 related articles for article (PubMed ID: 14987916)
21. Treatment of polycythemia vera.
Barbui T; Finazzi G
Haematologica; 1998 Feb; 83(2):143-9. PubMed ID: 9549926
[TBL] [Abstract][Full Text] [Related]
22. Diagnosis and therapy of polycythemia vera.
Lengfelder E; Merx K; Hehlmann R
Semin Thromb Hemost; 2006 Apr; 32(3):267-75. PubMed ID: 16673281
[TBL] [Abstract][Full Text] [Related]
23. The haematocrit and platelet target in polycythemia vera.
Di Nisio M; Barbui T; Di Gennaro L; Borrelli G; Finazzi G; Landolfi R; Leone G; Marfisi R; Porreca E; Ruggeri M; Rutjes AW; Tognoni G; Vannucchi AM; Marchioli R;
Br J Haematol; 2007 Jan; 136(2):249-59. PubMed ID: 17156406
[TBL] [Abstract][Full Text] [Related]
24. The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera.
Michiels JJ; Berneman Z; Schroyens W; Finazzi G; Budde U; van Vliet HH
Semin Thromb Hemost; 2006 Sep; 32(6):589-604. PubMed ID: 16977569
[TBL] [Abstract][Full Text] [Related]
25. Management of oral anticoagulant therapy in the real practice of an anticoagulation clinic: focus on atrial fibrillation.
Poli D; Antonucci E; Lombardi A; Cecchi E; Gensini GF; Abbate R; Prisco D
Blood Coagul Fibrinolysis; 2005 Oct; 16(7):491-4. PubMed ID: 16175008
[TBL] [Abstract][Full Text] [Related]
26. Arterial stenosis and atherothrombotic events in polycythemia vera and essential thrombocythemia.
Cucuianu A; Stoia M; Farcaş A; Dima D; Zdrenghea M; Paţiu M; Olinic D; Petrov L
Rom J Intern Med; 2006; 44(4):397-406. PubMed ID: 18386616
[TBL] [Abstract][Full Text] [Related]
27. Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia.
Passamonti F; Malabarba L; Orlandi E; Baratè C; Canevari A; Brusamolino E; Bonfichi M; Arcaini L; Caberlon S; Pascutto C; Lazzarino M
Haematologica; 2003 Jan; 88(1):13-8. PubMed ID: 12551821
[TBL] [Abstract][Full Text] [Related]
28. [Clinical analysis of 185 patients with polycythemia vera].
Bai J; Shao Z; Jing L; Liu H; Shi J; Zhao M; Fu R; He G; Sun J; Jia H; Qian L; Yang T; Yang C
Zhonghua Xue Ye Xue Za Zhi; 2002 Nov; 23(11):578-80. PubMed ID: 12482341
[TBL] [Abstract][Full Text] [Related]
29. Dilemma of antithrombotic therapy in anticoagulated atrial fibrillation patients squeezed between thrombosis and bleeding events: a single-centre experience.
Halbfass P; Janko S; Dorwarth U; Riess G; Antoni D; Hoffmann E
Europace; 2009 Jul; 11(7):957-60. PubMed ID: 19493910
[TBL] [Abstract][Full Text] [Related]
30. Polycythemia vera and mesenteric arterial thrombosis. A disease association resulting from decreased platelet sensitivity to aspirin.
Myers TJ; Steinberg WM; Rickles FR
Arch Intern Med; 1979 Jun; 139(6):695-8. PubMed ID: 443976
[TBL] [Abstract][Full Text] [Related]
31. Treatment of Budd-Chiari syndrome in a liver transplant unit, the role of transjugular intrahepatic porto-systemic shunt and liver transplantation.
Attwell A; Ludkowski M; Nash R; Kugelmas M
Aliment Pharmacol Ther; 2004 Oct; 20(8):867-73. PubMed ID: 15479358
[TBL] [Abstract][Full Text] [Related]
32. A 10 mg warfarin initiation nomogram is safe and effective in outpatients starting oral anticoagulant therapy for venous thromboembolism.
Monkman K; Lazo-Langner A; Kovacs MJ
Thromb Res; 2009 Jul; 124(3):275-80. PubMed ID: 19155056
[TBL] [Abstract][Full Text] [Related]
33. A prospective multicentre observational study on the management of patients on oral anticoagulation undergoing coronary artery stenting: rationale and design of the ongoing warfarin and coronary stenting (WAR-STENT) registry.
Rubboli A; Bolognese L; Di Pasquale G; Galvani M; La Vecchia L; Maggioni AP
J Cardiovasc Med (Hagerstown); 2009 Feb; 10(2):200-3. PubMed ID: 19377385
[TBL] [Abstract][Full Text] [Related]
34. [The risk factors for thrombosis, myelofibrosis and leukemia transformation in patients with polycythemia vera].
Bai J; Xue YP; Ye L; Yao JF; Zhou CL; Qian LS; Yang RC; Li HY; Zhang HY; Shao ZH
Zhonghua Xue Ye Xue Za Zhi; 2007 Oct; 28(10):685-8. PubMed ID: 18399175
[TBL] [Abstract][Full Text] [Related]
35. Thrombosis and bleeding in polycythemia vera and essential thrombocythemia: pathogenetic mechanisms and prevention.
Landolfi R; Cipriani MC; Novarese L
Best Pract Res Clin Haematol; 2006; 19(3):617-33. PubMed ID: 16781491
[TBL] [Abstract][Full Text] [Related]
36. Thromboembolic and/or bleeding complications in patients under oral anticoagulation followed at a tertiary hospital.
Pelicano N; Branco LM; Pinto A; Sá A; Timóteo AT; Feliciano J; Fiarresga A; Agapito AF; Palma MC; Quininha J
Rev Port Cardiol; 2005; 24(7-8):957-68. PubMed ID: 16240682
[TBL] [Abstract][Full Text] [Related]
37. [Use of oral anticoagulants to prevent central venous catheter-related thrombosis in hemodialysis].
Mandolfo S; Gallieni M
G Ital Nefrol; 2010; 27(5):490-7. PubMed ID: 20922680
[TBL] [Abstract][Full Text] [Related]
38. Risks of oral anticoagulant therapy with increasing age.
Torn M; Bollen WL; van der Meer FJ; van der Wall EE; Rosendaal FR
Arch Intern Med; 2005 Jul; 165(13):1527-32. PubMed ID: 16009869
[TBL] [Abstract][Full Text] [Related]
39. [Warfarin in the treatment of antiphospholipid syndrome].
Reshetniak TM; Kondrat'eva LV; Patrusheva NL; Patrushev LI
Ter Arkh; 2007; 79(5):47-54. PubMed ID: 17672075
[TBL] [Abstract][Full Text] [Related]
40. Clinical manifestations and outcomes of antithrombotic treatment of the Tan Tock Seng Hospital Singapore antiphospholipid syndrome cohort.
Tan BE; Thong BY; Shivananda S; Han WW; Chng HH
Lupus; 2009 Jul; 18(8):752-8. PubMed ID: 19502274
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
